zithromax and cefuroxime-axetil

zithromax has been researched along with cefuroxime-axetil* in 3 studies

Reviews

2 review(s) available for zithromax and cefuroxime-axetil

Article	Year
The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections. Advances in pediatric infectious diseases, 1994, Volume: 9 Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Cefixime; Cefotaxime; Cefpodoxime Proxetil; Cefprozil; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Child; Clarithromycin; Fluoroquinolones; Humans	1994
Lyme disease. Seminars in dermatology, 1993, Volume: 12, Issue:4 Years before the spirochetal etiology of Lyme disease was determined, the effectiveness of antibiotic treatment for erythema chronicum migrans had been established. Revisions in antibiotic treatment have evolved in concert with a growing understanding of the pathogenesis of Lyme disease. Current treatment recommendations are discussed. Topics: Adult; Animals; Anti-Bacterial Agents; Azithromycin; Borrelia burgdorferi Group; Cefuroxime; Child; Clinical Protocols; Clinical Trials as Topic; Erythema Chronicum Migrans; Humans; Lyme Disease; Microbial Sensitivity Tests; Prodrugs; Treatment Failure	1993

Article

Year

The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections.

Advances in pediatric infectious diseases, 1994, Volume: 9

Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Cefixime; Cefotaxime; Cefpodoxime Proxetil; Cefprozil; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Child; Clarithromycin; Fluoroquinolones; Humans

1994

Lyme disease.

Seminars in dermatology, 1993, Volume: 12, Issue:4

Years before the spirochetal etiology of Lyme disease was determined, the effectiveness of antibiotic treatment for erythema chronicum migrans had been established. Revisions in antibiotic treatment have evolved in concert with a growing understanding of the pathogenesis of Lyme disease. Current treatment recommendations are discussed.

Topics: Adult; Animals; Anti-Bacterial Agents; Azithromycin; Borrelia burgdorferi Group; Cefuroxime; Child; Clinical Protocols; Clinical Trials as Topic; Erythema Chronicum Migrans; Humans; Lyme Disease; Microbial Sensitivity Tests; Prodrugs; Treatment Failure

1993

Trials

1 trial(s) available for zithromax and cefuroxime-axetil

Article	Year
Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. International journal of antimicrobial agents, 1998, Volume: 10, Issue:4 The objective of this study was to compare the duration of serum bactericidal activity (SBA) for clarithromycin, azithromycin, and cefuroxime axetil in 12 young healthy volunteers after 5 days of therapy (dosed to steady-state) against two strains each of penicillin (PCN)-susceptible, -intermediate, and -resistant Streptococcus pneumoniae. This was a randomized, 3-way crossover study. All isolates were susceptible to clarithromycin (MICs 0.125 mg/l) and azithromycin (MICs 0.25-0.5 mg/l), while cefuroxime axetil susceptibilities correlated with PCN. Results showed that SBA was maintained for 100% of the dosing interval for clarithromycin and 50-100% for azithromycin regardless of PCN susceptibility when standard doses were employed. Cefuroxime axetil was active only against the PCN-susceptible isolate for 50% of the dosing interval, indicating that it should only be used for PCN-susceptible S. pneumoniae. Topics: Anti-Bacterial Agents; Azithromycin; Cefuroxime; Cephalosporins; Clarithromycin; Cross-Over Studies; Drug Administration Schedule; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Penicillin Resistance; Serum Bactericidal Test; Streptococcus pneumoniae	1998

Article

Year

Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.

International journal of antimicrobial agents, 1998, Volume: 10, Issue:4

The objective of this study was to compare the duration of serum bactericidal activity (SBA) for clarithromycin, azithromycin, and cefuroxime axetil in 12 young healthy volunteers after 5 days of therapy (dosed to steady-state) against two strains each of penicillin (PCN)-susceptible, -intermediate, and -resistant Streptococcus pneumoniae. This was a randomized, 3-way crossover study. All isolates were susceptible to clarithromycin (MICs 0.125 mg/l) and azithromycin (MICs 0.25-0.5 mg/l), while cefuroxime axetil susceptibilities correlated with PCN. Results showed that SBA was maintained for 100% of the dosing interval for clarithromycin and 50-100% for azithromycin regardless of PCN susceptibility when standard doses were employed. Cefuroxime axetil was active only against the PCN-susceptible isolate for 50% of the dosing interval, indicating that it should only be used for PCN-susceptible S. pneumoniae.

Topics: Anti-Bacterial Agents; Azithromycin; Cefuroxime; Cephalosporins; Clarithromycin; Cross-Over Studies; Drug Administration Schedule; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Penicillin Resistance; Serum Bactericidal Test; Streptococcus pneumoniae

1998